Quarterly ResultMay 7, 2026, 04:23 PM
4D Molecular Therapeutics Q1 Net Loss Widens to $68.8M
AI Summary
4D Molecular Therapeutics reported a net loss of $68.8 million for the first quarter of 2026, a significant increase from $48.0 million in the same period last year, primarily driven by a substantial rise in research and development expenses. Collaboration and license revenue saw a notable increase to $3.0 million, largely due to the Otsuka Agreement. The company ended the quarter with $72.5 million in cash and cash equivalents, and expects to continue incurring operating losses and negative cash flows, necessitating additional funding.
Key Highlights
- Net loss for Q1 2026 widened to $68.8 million, from $48.0 million in Q1 2025.
- Collaboration and license revenue surged to $3.0 million in Q1 2026, from $14 thousand in Q1 2025.
- Research and development expenses increased 59.6% year-over-year to $65.0 million in Q1 2026.
- Net cash used in operating activities was $68.1 million for the three months ended March 31, 2026.
- Cash and cash equivalents totaled $72.5 million as of March 31, 2026.
- Accumulated deficit reached $785.1 million as of March 31, 2026.
- The company expects continued operating losses and negative cash flows for the foreseeable future.
- Net proceeds from the November 2025 underwritten offering were approximately $93.3 million.
Price Impact
More from FDMT